Ty Brender - Concepedia

Concepedia

Author

Ty Brender

Bristol-Myers Squibb (United States)

Also Known As

Ty Brender, Ty M. Brender

14

Publications

1.7K

Citations

9

H-Index

29

Concepts

All Affiliations

Bristol-Myers Squibb (United States)HistoGenetics (United States)Institute for In Vitro Sciences

TB

About

Ty Brender is an author at Bristol-Myers Squibb (United States) specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	734
2	Engineering	1	1	56
3	Natural Sciences	1	1	83
4	Allergy	1	1	352
5	Biochemistry	1	1	83

Ty Brender

×

9

Publications

1.7K

Citations

9

H-Index

	Year	Citations
Interleukin 20 Hal Blumberg, Darrell Conklin, Wenfeng Xu, Cell	2001	546
Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F Rolf Kuestner, David W. Taft, Aaron C. Haran, The Journal of Immunology InflammationCytokineAllergyAutoimmune DiseaseIl-17rc Functions	2007	352
Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes Julia Parrish-Novak, Wenfeng Xu, Ty Brender, Journal of Biological Chemistry	2002	267
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist Wenfeng Xu, Scott Presnell, Julia Parrish-Novak, Proceedings of the National Academy of Sciences InflammationInflammatory ResponsesCytokineAutoimmune DiseaseImmune Cell Development	2001	213
Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis Jing Li, Hui Wei, Stanley R. Krystek, Analytical Chemistry Proteins Mass SpectrometryImmunologyMolecular BiologyAntigen ProcessingImmunotherapy	2017	83
Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes Keli L. Hippen, Christoph Bucher, Dawn K. Schirm, Blood	2011	77
Engineering of stable bispecific antibodies targeting IL-17A and IL-23 Robert L. Mabry, Katherine E. Lewis, Margaret Moore, Protein Engineering Design and Selection Stable Bispecific AntibodiesEngineeringImmunologyImmunologic MechanismImmunotherapeutics	2009	56
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models Natalie Bezman, Amy Jhatakia, Alper Y. Kearney, Blood Advances	2017	53
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. Heather Metz, Monica Childs, Jamie Brevik, Journal of Clinical Oncology Sbt6050 BindImmunologyBiological TherapyInnate ImmunityHer2-directed Tlr8 Therapeutic	2020	30

Page 1